<DOC>
	<DOCNO>NCT02484911</DOCNO>
	<brief_summary>The purpose study mainly evaluate efficacy safety aprepitant combination olanzapine , palonosetron dexamethasone prevention chemotherapy-induced nausea vomiting ( CINV ) patient receive highly moderately emetogenic chemotherapy .</brief_summary>
	<brief_title>Aprepitant , Olanzapine , Palonosetron Dexamethasone Prevention Chemotherapy-induced Nausea Vomiting</brief_title>
	<detailed_description>Eligible patient randomize receive different antiemetic regimen . In experimental group , patient receive aprepitant , olanzapine , palonosetron dexamethasone .In group , patient accept dose aprepitant , palonosetron dexamethasone .During treatment , grade nausea vomit record order evaluate complete response rate CINV , nausea patient measure visual analogue scale ( VAS ) , adverse event record well .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>1 . 18 year age old 2 . Histologically cytologically confirm malignant disease 3 . Accept chemotherapy first time 4 . Patients receive high emetogenic cancer chemotherapy ( HEC ) ( cisplatin &gt; =70mg/m2 , adriamycin combination cyclophosphamide , cyclophosphamide &gt; =1500mg/m2 , adriamycin &gt; 60mg/m2 , epirubicin &gt; 90mg/m2 , dacarbazine，ifosfamide &gt; =2g/m2 ) moderate emetogenic chemotherapy cancer ( carboplatin &gt; =300mg/m2 , cyclophosphamide &gt; =6001000mg/m2 , adriamycin &gt; 50mg/m2 ) 5 . Written inform consent 1 . Pregnant breastfeed 2 . Uncontrolled psychosis history 3 . Inability unwillingness understand cooperate study procedures 4 . Central nervous system tumor primary secondary 5 . Concurrent abdominal radiotherapy 6 . History uncontrolled diabetes mellitus 7 . Patients prostatic hyperplasia ，paralytic ileus，narrow foot glaucoma . 8 . Known cardiac arrhythmia , uncontrolled congestive heart failure , acute myocardial infarction previous six month 9 . Preexisting nausea vomit 10 . Inadequate hematological function abnormal liver renal function . 11 . History sensitivity olanzapine 12 . Concurrent application quinolone antibiotic therapy 13 . Treatment another antipsychotic agent risperidone , quetiapine , clozapine , phenothiazine , butyrophenone 30 day prior chemotherapy . 14 . Cytochrome P450 3A4 substrate within 7 day ( terfenadine , cisapride , astemizole , pimozide ) 15 . Concurrent application systemic corticosteroid 16 . Active infection gastrointestinal dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>chemotherapy nausea vomit</keyword>
</DOC>